glp-1 receptor agonist blood pressure reduction Endogenous Activation of Glucagon-Like Peptide-1 Contributes to Control Cardiovascular Protective Properties of GLP-1

doi: 10.14218/JCTH.2024.00271, 23

References (this section): FDA: Concerns with unapproved GLP-1 drugs used for weight loss (mentions retatrutide not FDA-approved) Drugs.com: Retatrutide status & regulatory history How does retatrutide work

[DOI] [PubMed] [Google Scholar] 365.Svendsen B., Larsen O., Gabe M.B.N., Christiansen C.B., Rosenkilde M.M., Drucker D.J

Results revealed that gastrointestinal symptoms such as nausea, vomiting, and abdominal discomfort, which were dose-dependent and mainly mild in severity, were the side effects of LY3437943

Endotoxin contamination triggers inflammatory responses

Macconell L, Pencek R, Li Y, Maggs D, Porter L